A Study to Evaluate Safety and Efficacy of NovoSeven® in Patients With Glanzmann's Thrombasthenia in Japan
Status:
Completed
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
This study is conducted in Asia. The aim of the study is to evaluate the safety and efficacy
of NovoSeven® (activated recombinant factor VII, eptacog alfa (activated)) during bleeding
episodes and for the prevention of bleeding during surgery/delivery in patients with
Glanzmann's thrombasthenia (GT)/Glanzmann's disease.